Shree Ganesh Remedies Limited announced the re-appointment of Mr. Parth Chandulal Kothia as Whole Time Director and Chief Financial Officer for an additional five-year term. The board of directors approved this decision on January 16, 2026, based on the recommendation of the Nomination and Remuneration Committee.

Board Meeting Outcomes

The board meeting, which commenced at 4:45 PM and concluded at 6:00 PM on January 16, 2026, addressed Mr. Kothia's re-appointment as his current term expires on January 17, 2026. The re-appointment is effective from January 17, 2026, and will continue until January 16, 2031, subject to approval from the company's members.

Director Profile and Qualifications

Mr. Parth Chandulal Kothia brings significant expertise to his role as Whole Time Director and CFO. He is a graduate in Chemical Engineering and holds a Master of Science degree in Global Finance from Fordham University, USA. His professional experience spans over five years in Business Development for Pharmaceutical Intermediates and Specialty Chemicals.

Prior to joining the company, Mr. Kothia worked in the Private Equity and Venture Capital industry in the USA, gaining extensive understanding of Finance and Capital Markets. Since joining Shree Ganesh Remedies Limited in 2021, he has been instrumental in driving growth through his marketing and finance initiatives, which have had an organization-wide impact.

Shareholding and Relationships

Mr. Kothia currently holds 131,704 equity shares in the company. He is the son of Mr. Chandulal Manubhai Kothia, who serves as the Chairman and Managing Director of Shree Ganesh Remedies Limited.

Regulatory Compliance

The company confirmed that Mr. Parth Chandulal Kothia and all existing directors are not debarred from holding directorial positions by any SEBI order or other regulatory authority. This disclosure complies with stock exchange circulars dated June 20, 2018, and SEBI regulations regarding director appointments.

The re-appointment reflects the company's confidence in Mr. Kothia's leadership capabilities and his contribution to the organization's growth trajectory in the pharmaceutical sector.

Shree Ganesh Remedies Limited , a prominent player in the pharmaceutical sector, has announced significant changes to its board composition and audit structure. The company's Board of Directors has made key decisions aimed at enhancing corporate governance and maintaining financial oversight.

New Independent Director Appointment

Ms. Shruti Sohane has been appointed as an Additional Director (Non-Executive, Independent) of Shree Ganesh Remedies Limited. The appointment, effective from August 08, 2025, is for a five-year term, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Ms. Sohane brings a wealth of experience to the board:

• Qualified Company Secretary with over a decade of experience in corporate governance and legal compliance
• Member of the Institute of Company Secretaries of India (ICSI) since 2014
• Commerce and law graduate from Nagpur University
• Known for her expertise in corporate laws, exceptional drafting skills, and solution-oriented approach to legal and regulatory matters

The company has confirmed that Ms. Sohane has not been debarred from holding the office of Director by any SEBI Order or other authority, ensuring compliance with regulatory requirements.

Cost Auditor Reappointment

In a move to maintain financial transparency and cost efficiency, Shree Ganesh Remedies has reappointed M/s. M. I. Prajapati & Associates as the Cost Auditor for the financial year 2025-2026. The reappointment comes with a remuneration of Rs. 55,000.00 plus applicable taxes, subject to shareholder approval at the upcoming AGM.

Key details of the Cost Auditor:

• CMA Mitesh Prajapati, proprietor of M. I. Prajapati & Associates, is a Fellow Member of ICMAI
• Completed CMA in 2011, ranking 71st All India in intermediate examinations
• Over 15 years of experience in preparing cost records and audit reports across various industries

Additional Board Decisions

The Board of Directors also made several other important decisions:

1. Appointed Mr. Vishal Thawani of M/s. Vishal Thawani & Associates, Practicing Company Secretaries, as the Scrutinizer for the e-voting process at the 30th AGM.
2. Approved the Notice for the 30th AGM along with the Directors' Report and its annexures for the year ended March 31, 2025.

These decisions reflect Shree Ganesh Remedies' commitment to maintaining high standards of corporate governance and ensuring transparent communication with its shareholders.

The board meeting, which took place on August 08, 2025, commenced at 12:30 p.m. and concluded at 01:15 p.m. These strategic moves are expected to strengthen the company's leadership and financial oversight in the pharmaceutical industry.